Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443233 | 0.98 | — | — | |
| Trimethylammonium SCHEMBL27489681 | 0.91 | CYP1A2 (0.61) | CYP1A2CYP2D6 | |
| Dimethylamine SCHEMBL27963870 | 0.91 | CYP1A2 (0.50) | CYP1A2CYP2D6 | |
| SCHEMBL28833935 | 0.83 | CYP1A2 (0.40) | CYP1A2CYP2D6DNM1MEN1KMT2A | |
| SCHEMBL706895 | 0.79 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| SCHEMBL708799 | 0.79 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| SCHEMBL707889 | 0.79 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| SCHEMBL707888 | 0.79 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28596072 | 0.78 | — | — | |
| SCHEMBL5183227 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4461733-A1 | 1-AMINOBENZO[4,5]IMIDAZO[1,2-A]PYRAZINE-3-FORMAMIDE COMPOUND, AND PREPARATION THEREFOR AND USE THEREOF | Sun Yat-Sen University (CN) | 2024-11-13 | — | — | EP | disclosed |
| CN-112351976-B | Taxane-lipid-polysaccharide double-type coupling body, preparation method and application thereof | 圣多利康制药责任有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-109715192-A | Drug combination for converting neoplastic cells into non-neoplastic cells and use thereof | 伊斯迪德股份公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109715195-A | Drug combination for converting neoplastic cells into non-neoplastic cells and use thereof | 伊斯迪德股份公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109311957-A | Compound for inducing tissue formation and application thereof | 伊斯迪德股份公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109311956-A | Compound for inducing tissue formation and application thereof | 伊斯迪德股份公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-101605779-B | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors | SQUIBB BRISTOL MYERS CO US | 2013-11-20 | — | — | CN | disclosed |
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-6080846-A | RECOMBINANT DNA OF NUCLEOTIDE SEQUENCE CODING FOR B EPITOPE OF ENV GLYCOPROTEIN OF AN IMMUNODEFICIENCY VIRUS LINKED TO T EPITOPE OF NEF PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS-1; FOR PROTECTIVE VACCINES; DIAGNOSIS | INSTITUT PASTEUR (FR) | 2000-06-27 | — | — | US | disclosed |
| US-5763203-A | Immobilization and separation of cells and other particles | SINVENT AS (NO) | 1998-06-09 | — | — | US | disclosed |
| US-5688914-A | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | INSTITUT PASTEUR (FR) | 1997-11-18 | — | — | US | disclosed |
| EP-0688430-B1 | IMMOBILISATION AND SEPARATION OF CELLS AND OTHER PARTICLES | SINVENT AS (NO) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996024617-A1 | DESAMINONONAPEPTIDES, PROCESS FOR PREPARING THE SAME AND THEIR USE FOR PREPARING ELCATONIN | LONZA AG (CH) | 1996-08-15 | — | — | WO | disclosed |
| EP-0688430-A1 | IMMOBILISATION AND SEPARATION OF CELLS AND OTHER PARTICLES | SINVENT AS (NO) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994020858-A1 | IMMOBILISATION AND SEPARATION OF CELLS AND OTHER PARTICLES | SINVENT A/S (NO) | 1994-09-15 | — | — | WO | disclosed |
| US-4954512-A | Anti-ulcer composition | Okamoto, Shosuke (JP) | 1990-09-04 | — | — | US | disclosed |
| EP-0317959-A2 | Anti-ulcer composition | Okamoto, Shosuke (JP) | 1989-05-31 | — | — | EP | disclosed |
| US-4292404-A | Method for determining the activity of the angiotensin-converting enzyme | FUJIZOKI PHARMACEUTICAL CO., LTD. (JP) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | CYP1A2 21/4885CYP2D6 23/4885DNM1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.